NCT03822078已完成1 期
A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 162 Administered Subcutaneously to Japanese Postmenopausal Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 45
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
The primary objective was to evaluate the safety and tolerability of denosumab (AMG 162) after a single subcutaneous administration in Japanese postmenopausal women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 接受健康志愿者
- 否
入选标准
- •ambulatory women between the ages of 40 and 64 years, inclusive
- •postmenopausal, defined as amenorrheic for at least 24 months
- •clinically acceptable physical exam
- •clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) within normal limits or clinically acceptable to the investigator/sponsor at the time of screening with the exception of aspartate transaminase (AST) and alkaline phosphatase (ALT), which must be < 1.25 times the upper limit of normal, or gamma-glutamyl transpeptidase (GGT), which must be < 1.5 times the upper limit of normal
- •normal or clinically acceptable electrocardiogram (ECG) (12-lead reporting ventricular rate and PR, QRS, QT, and QTc intervals)
- •body mass index between 17 and 27
- •willing to sign an approved informed consent form before any study-specific assessments and oral consultations are performed
排除标准
- •administration of medications within 6 months before investigational product administration that are known to effect bone metabolism, including but not limited to the following: calcitonin, parathyroid hormone (or any derivative), supplemental vitamin D (> 1000 IU/day), glucocorticosteroids (inhaled or topical corticosteroids administered more than 2 weeks before the date of informed consent were allowed), anabolic steroids, calcitriol and available analogues, diuretics
- •administration of the following medications within 12 months before study drug administration: bisphosphonates, fluoride for osteoporosis
- •diagnosed with any condition that affects bone metabolism
- •greatly differing levels of physical activity compared with the 6 months before investigational product administration or constant levels of intense physical activities
- •routine alcohol intake of ≥ 2 drinks/day, on average, within 6 months of investigational product administration
- •known sensitivity to any drugs
- •positive test results for hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus antigen/antibody, syphilis
- •receiving or received any investigational drug (or was currently using an investigational device) within 4 months before receiving investigational product
- •donated any amount of blood within 16 weeks, or over 400 mL (Note: not 400 mL but 200 mL, for the subjects who were to be enrolled into cohorts 4 or 5) within 1 year of the start day of screening
- •subject had previously entered this study
- •any other condition that might have reduced the chance of obtaining data (eg, known poor compliance) required by the protocol or that might have compromised the ability to give truly informed consent
研究组 & 干预措施
Placebo
Placebo Comparator
Participants received a single subcutaneous injection of placebo to denosumab on day 1.
干预措施: Placebo (Drug)
Denosumab
Experimental
Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
干预措施: Denosumab (Biological)
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: From day 1 up to 4 months for participants assigned to the 0.03 or 0.1 mg/kg dose cohorts, up to 6 months for participants assigned to the 0.3 mg/kg dose cohort and for up to 9 months for participants assigned to the 1.0 or 3.0 mg/kg dose cohorts
次要结局
- Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)(Baseline and day 2, 3, 5, 8, 15, 29, 57, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only))
- Maximum Observed Concentration of Denosumab (Cmax)(Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts)
- Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration(Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts)
- Percent Change From Baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (N-Tx/Cr)(Baseline and day 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only).)
- Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab(Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts)
- Time to Maximum Observed Concentration (Tmax) of Denosumab(Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts)
- Apparent Clearance (CL/F) of Denosumab(Day 1 predose and 5 minutes, 1, 4, 8, 12, 24, hours, days 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85, 99, 113, also days 141 and 169 for participants in the 0.3, 1.0, or 3.0 mg/kg cohorts and days 197, 225, and 253 for the 1.0 or 3.0 mg/kg dose cohorts)
- Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP)(Baseline and day 8, 15, 22, 29, 43, 57, 71, 85, 99, 113 (for all dose cohorts), 141, 169 (0.3, 1.0, and 3.0 mg/kg cohorts only), 197, 225, and 253, 281, and 309 (1.0 and 3.0 mg/kg cohorts only))
研究者
相似试验
已完成
2 期
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00095498Amgen227
已完成
3 期
Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyBone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple MyelomaNCT00950911Amgen35
已完成
2 期
Denosumab vs Placebo in Patients With Thalassemia Major and OsteoporosisThalassemia MajorOsteoporosisNCT02559648Ersi Voskaridou63
已完成
2 期
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell TransplantAllogeneic Hematopoietic Stem Cell Transplantation RecipientOsteopeniaOsteoporosisNCT03925532Roswell Park Cancer Institute30
已完成
2 期
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerMetastasesBone Metastases in Subjects With Advanced Breast CancerBreast CancerNCT00091832Amgen255